SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Battalion Oil Corp. engages in the acquisition, production, exploration, and development of liquids-rich oil and natural gas assets in the Delaware Basin. The company was founded in 1987 and is headquartered in Houston, TX.

Battalion Oil Corp - Ordinary Shares (New)

Battalion Oil is experiencing a dramatic surge driven by rising oil prices amidst escalating Middle East tensions and concerns over the Strait of Hormuz. The community is buzzing with talks of a significant short squeeze, high trading volumes, and the stock's potential for further explosive gains, leaving many shorts 'cooked'.

Snap, Inc. is a technology company, which engages in the provision of a visual messaging application that was created to help people communicate through short videos and images. The company was founded by Frank Reginald Brown IV, Evan Thomas Spiegel, and Robert C. Murphy in 2010 and is headquartered in Santa Monica, CA.

Snap Inc - Ordinary Shares - Class A

Snap Inc

SNAP is trending as investors and the community are actively discussing its recent achievement of profitability, a $1B annualized direct revenue run rate, and over 25 million Snapchat+ subscribers, signaling a potential turnaround. Many believe the stock is significantly undervalued given these operational milestones and its leadership in AI/AR technology, fueling speculation of a potential acquisition.

Gorilla Technology Group, Inc. engages in the provision of video intelligence, Internet of Things (IoT) security, edge AI data analytics, and operational technology security solutions and services in Asia Pacific. It operates through the following segments: Video IoT, Security Convergence, and Other. The company was founded by Spincer Koh in May 2001 and is headquartered in London, the United Kingdom.

Gorilla Technology Group Inc

Gorilla Technology Group is trending after reporting record Q4 and full-year 2025 revenue with significant profitability improvements, sparking community debate over its perceived undervaluation and multi-billion-dollar AI infrastructure pipeline against persistent skepticism regarding management's past execution and the stock's price action.

SSgA Active Trust - State Street SPDR S&P 500 ETF Trust

Escalating geopolitical tensions in the Middle East, driven by reported attacks on US interests and threats to the Strait of Hormuz, are sparking community debate on whether the market's current resilience is a manipulated 'patriotic bump' or a genuine buying opportunity amidst surging oil prices and anticipated volatility for the broader SPY.

Lumentum Holdings, Inc. engages in the provision of optical and photonic products. It operates through the Cloud and Networking, and Industrial Tech segments. The Cloud and Networking segment refers to a portfolio of optical and photonic components, modules, and subsystems. The Industrial Tech segment includes solid-state lasers, kilowatt-class fiber lasers, ultrafast lasers, diode lasers, and gas lasers. The company was founded in 1979 and is headquartered in San Jose, CA.

Lumentum Holdings Inc

Lumentum is surging amid community excitement over a multi-billion dollar strategic investment by a leading AI chipmaker to advance optical infrastructure, reinforcing its perceived critical role in next-gen data centers, though its high valuation is actively debated among investors.

CoreWeave, Inc. engages in the powers of the creation and delivery of the intelligence that drives innovation. It offers a solution used by organizations of all sizes that require sophisticated AI computing, from the largest of enterprises to small, well-funded start-ups. The company was founded by Michael Intrator, Brian Venturo, and Brannin McBee on September 21, 2017 and is headquartered in Livingston, NJ.

CoreWeave Inc. - Ordinary Shares - Class A

CoreWeave Inc

CoreWeave is trending downward following an earnings report revealing significantly higher capital expenditure plans and softer guidance, raising investor concerns about its debt and path to profitability. Despite the sharp decline, a divided community debates the long-term potential, with bulls emphasizing the company's substantial AI infrastructure backlog and recent bullish developments surrounding its key customer, OpenAI.

BlackRock Institutional Trust Company N.A. - iShares MSCI South Korea ETF

iShares MSCI South Korea ETF

The iShares MSCI South Korea ETF (EWY) is trending as its major holdings, Samsung and SK Hynix, surge amidst the AI-driven memory supercycle and recent DRAM/NAND price hikes. While some debate if its parabolic gains represent a market bubble, others view current dips as tactical buying opportunities, citing robust fundamentals and attractive valuations compared to US benchmarks.

Indonesia Energy Corp. Ltd. operates as an oil and gas, exploration, and production company. It engages in oil and gas assets portfolio with a mix between medium-sized producing blocks and exploration blocks with significant resources. Its portfolio includes Kruh, Citarum, and Rangkas Area. The company was founded by James J. Huang and Wirawan Jusuf in 2014 and is headquartered in Jakarta, Indonesia.

Indonesia Energy Corp Ltd

Indonesia Energy Corp Ltd is trending amid escalating Middle East tensions and threats to oil shipping in the Strait of Hormuz, which are driving crude prices higher across the sector. The community is actively discussing INDO's potential to catch up to other booming energy stocks, alongside anticipation of news regarding its drilling operations.

Larimar Therapeutics, Inc. Is a clinical-stage biopharmaceutical company, which engages in the research, development, and commercialization of novel therapeutics mitochondrial disorders and Friedreich's ataxia. The company was founded in 2005 and is headquartered in Bala Cynwyd, PA.

Larimar Therapeutics Inc

Larimar Therapeutics is experiencing significant discussion after receiving FDA Breakthrough Therapy Designation for its Friedreich's Ataxia treatment, nomlabofusp, sparking bullish sentiment and comparisons to multi-billion dollar acquisitions, while a recently priced public offering at $5.00 per share drives ongoing debate regarding immediate dilution versus funding a promising pipeline.

Venture Global, Inc. engages in the development and construction of liquefied natural gas production, establishing us as a rapidly growing company delivering critical LNG to the world. It projects include Calcasieu, Plaquemines, CP2, CP3 and Delta projects. The company was founded by Michael Sabel and Robert Pender in 2023 and is headquartered in Arlington, VA.

Venture Global Inc. - Ordinary Shares - Class A

Venture Global Inc

Venture Global Inc is trending due to a strong Q4 earnings report and a significant surge in global LNG prices, driven by escalating Middle East tensions and production halts in major exporting regions. The community is actively discussing VG's unique position to capitalize on increased spot demand, fueling anticipation of a short squeeze and a re-evaluation of its undervalued status.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

EGFR-NSCLC Market to Observe Stunning Growth at a CAGR of 9.6% During the Forecast Period (2025-2034)  DelveInsight

EGFR-NSCLC Market to Observe Stunning Growth at a CAGR of 9.6% During the Forecast Period (2025-2034) | DelveInsight EGFR-NSCLC Market to Observe Stunning Growth at a CAGR of 9.6% During the Forecast...

Lantern Pharma Receives FDA Orphan Drug Designation For LP-284

(RTTNews) - Lantern Pharma Inc. (LTRN) on Tuesday announced, that the U.S. Food and Drug Administration has given Orphan Drug Designation to LP-284 for treatment of soft tissue sarcomas...

Lantern Pharma's LP-284 Receives FDA Orphan Drug Designation for Soft Tissue Sarcomas

Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage biopharmaceutical company using artificial intelligence to transform the cost, pace, and timeline of oncology drug discovery and development...

Lantern Pharma Announces Establishing an A.I. Center of Excellence in India to Industrialize the RADR Platform and Accelerate Global Development Opportunities with BioPharma Companies

Lantern Pharma Inc. (NASDAQ: LTRN), a pioneer in AI-driven precision oncology and computational therapeutic development, today announced the establishment of an A.I. Center of Excellence and Advanced...

Lantern Pharma Reports Third Quarter 2025 Financial Results and Provides Business Updates

Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage biopharmaceutical company leveraging its proprietary RADR artificial intelligence (AI) and machine learning (ML) platform to transform the cost...

Lantern Pharma to Report Third Quarter 2025 Operating & Financial Results on November 13th, 2025 at 9:00 a.m. ET

Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (AI) company developing targeted and transformative cancer therapies using its proprietary RADR AI and machine learning (ML) platform...

Lantern Pharma to Present AI-Driven Cancer Drug Development & Research Platforms at Inaugural AI for Biology and Medicine Symposium at UNT

Lantern Pharma Inc. (NASDAQ: LTRN) Lantern today announced it will present two commercially deployed AI research platforms at the inaugural AI for Biology and Medicine (AI4BM) symposium at the...

Lantern Pharma Presents LP-284 Clinical Data at 25th LL&M Congress, Highlighting Complete Response in Therapeutically Exhausted DLBCL Patient & Therapeutic Potential in Advanced B-Cell Cancers.

Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage biopharmaceutical company leveraging its proprietary RADR artificial intelligence platform to transform oncology drug discovery and development...

Lantern Pharma to Present at the ThinkEquity Conference in NYC on October 30, 2025

Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (AI) company dedicated to developing cancer therapies and transforming the cost, pace, and timeline of oncology drug discovery and...

Lantern Pharma, Inc. engages in the development of drugs through leveraging artificial intelligence, machine learning, and genomic data. Its portfolio includes LP-100, LP-300, and LP-184. The company was founded by Arun K. Asaithambi, Gregory T. Tobin, and Peter L. Nara on November 7, 2013 and is headquartered in Dallas, TX.

Lantern Pharma Inc

Beat EPS and revenue

Beat EPS, miss revenue

Miss EPS, beat revenue

Miss EPS and revenue

What do you expect from $MDB earnings today?

Current Price	$2.68
Prev Close	$2.82
Open	$2.79
Dividend Yield	0.00%
50-Day Moving Average	$3.13
Beta	1.54
Avg. Volume	55,862.50
PE Ratio	-1.61

52-Week High	$5.74
52-Week Low	$2.45
Market Capitalization	$31.54M
EPS (Annual)	-$1.93
Price to Book	3.25
Revenue Per Employee	$0.00

LTRN
Lantern Pharma Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest LTRN News

LTRNLantern Pharma Inc